Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

Heng Ren Partners Demands Sinovac (SVA) Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading Mar 20, 2025 11:06AM

Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading Mar 20, 2025 11:05AM

SINOVAC Reports Unaudited First Half of 2024 Financial Results Aug 16, 2024 08:54AM

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F Apr 29, 2024 05:53PM

SINOVAC Reports Unaudited First Half of 2023 Financial Results Aug 15, 2023 06:00AM

May 1, 2023 06:00AM SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
Dec 29, 2022 08:30AM SINOVAC Reports Unaudited First Half of 2022 Financial Results
Apr 29, 2022 06:30PM SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
Dec 30, 2021 04:05PM SINOVAC Reports Unaudited First Half of 2021 Financial Results
Dec 9, 2021 02:26PM Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
Apr 22, 2021 06:51PM Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
Dec 7, 2020 07:30AM Sinovac Reports Unaudited Third Quarter 2020 Financial Results
Aug 28, 2020 04:15PM Sinovac Reports Unaudited Second Quarter 2020 Financial Results
Jun 30, 2020 09:20AM Sinovac Reports Unaudited First Quarter 2020 Financial Results
Apr 30, 2020 04:29PM Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F
Nov 15, 2019 08:40AM Sinovac Reports Unaudited Third Quarter 2019 Financial Results
Aug 15, 2019 04:05PM Sinovac Reports Unaudited Second Quarter 2019 Financial Results
Mar 8, 2019 06:28PM Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
Feb 22, 2019 05:15PM Sinovac Determines Trigger Event Occurred Under Rights Agreement
Feb 11, 2016 04:52PM Form SC 13G/A SINOVAC BIOTECH LTD Filed by: ORBIMED ADVISORS LLC
Feb 17, 2015 03:42PM Form SC 13G SINOVAC BIOTECH LTD Filed by: ORBIMED ADVISORS LLC

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed